FDA Accepts Isatuximab for Priority Review for Treatment of Transplant-Ineligible Multiple Myeloma Pharmacy Times, 28 May 2024 The FDA has accepted for priority review the supplemental biologics license application for isatuximab (Sarclisa; Sanofi-aventis…